Collectively, our findings demonstrate that dual TDO2/IDO1 inhibition is a promising therapeutic avenue for the blockade of TRP catabolism to reduce TNBC progression to metastatic disease. The gene discussed is IDO1; the disease is metastatic neoplasm.